KRAS and colorectal carcinoma: With respect to CRC driver mutations, NK score was significantly enriched in those patients with BRAF mutant (Figure 7G) or KRAS wildtype (Figure 7H) genotypes, although there was no association with TP53 status (Figure S8D).